Podcasts about Janssen

Send a textPodcast 3: Teaching Strategies and Education TipsDNP Website Link: https://amrossi359.wixsite.com/mysitePost-Survey Link: https://ufl.qualtrics.com/jfe/form/SV_3XjGBKEzMxll6HcThis is part three of a three-part podcast series. In this episode, we will discuss teaching strategies and education tips. ReferencesMuijsenberg, A. J., Houben-Wilke, S., Zeng, Y., Spruit, M. A., & Janssen, D. J. (2022). Methods to Assess Adults' Learning Styles and Factors Affecting Learning in Health Education: A Scoping Review. Patient Education and Counseling, 107, 107588. https://doi.org/10.1016/j.pec.2022.107588 Wong, C. I., Desrochers, M. D., Conway, M., Stuver, S. O., Mahan, R. M., & Billett, A. L. (2023). Improving Home Caregiver Independence with Central Line Care for Pediatric Cancer Patients. PEDIATRICS, 151(4). https://doi.org/10.1542/peds.2022-056617 

Breaking bread together is a spiritual activity and a venue for spiritual infilling.

Osteosarcoma Webinar Series: David Ulmert, MD, PhD, an Associate Professor at UCLA, discusses his OutSmarting Osteosarcoma funded work (Because of Sydney) on high-throughput characterization of pathobiological responses in osteosarcoma tumors treated with LRRC15-targeted radiotherapy to uncover curative co-treatment approaches.Dr. Ulmert will discuss his lab's work investigating how osteosarcoma responds to LRRC15-targeted radiotherapy, with patient translation anticipated this year. Using high-throughput technologies, the team will identify biomarkers, predictive models, and key transcriptional regulators driving the TGFβ–LRRC15 axis. He will review how radiopathobiological changes and immune reprogramming are being mapped to uncover druggable events and inform co-treatment strategies, accelerating near-term impact on patient studies and next-generation therapeutic development.Dr. David Ulmert is an expert in oncology and biotechnology, specializing in cancer biomarkers and targeted therapies. His research focuses on antigens secreted by luminal tissues as novel cancer-specific targets and circulating biomarkers. He developed high-affinity antibodies against androgen receptor-regulated enzymes hK2 and PSA, now in clinical trials across the US, Europe, and Australia—in collaboration with Janssen—for radioimmunotheranostics, CAR-T therapy, and bispecific targeting. His lab also developed DUNP19, an LRRC15-targeting antibody licensed to Lantheus, with a Phase 1 trial in osteosarcoma planned for 2025. Dr. Ulmert leads UCLA's Preclinical Theranostics Program and conducts population-based studies on cancer biomarkers and risk factors with international collaborators. He is widely recognized for advancing prostate cancer research and translational immunotheranostics.

Januari was top. Februari begint veelbelovend. Met een kinderverjaardag voor de deur. Steeds vaker klinkt het geluid dat drinken op een kinderverjaardag not done is. We geven onze mening en trekken een voor ons onderbouwde conclusie.  Juan vond in de bodembak bij  Getränke Hoffmann iets interessants. Namelijk een Brewdog Pumpkin Rush Spiced Ale uit de bodembak. Niet te doen.  In deze 2-wekelijkse podcast praten Juan en Marc kort bij. De één zorgt voor het bier en de ander voor het onderwerp. 

Theo Janssen, voetbalicoon en huidig trainer van De Treffers, schuift aan bij Alex Pastoor voor een openhartig gesprek over roken, voetbal, leiderschap en de kunst van het trainen. Van zijn tijd bij Vitesse, FC Twente en Ajax tot zijn huidige rol als trainer. Hoe ga je als speler om met discussies tussen trainers en spelers? Waarom is de 'waarom-vraag' zo cruciaal in de ontwikkeling van jonge voetballers? En hoe verras je spelers nog in een tijd waarin alles al voorbereid lijkt? Janssen reflecteert op zijn samenwerking met trainers als Ronald Koeman en Fred Rutten, en vertelt hoe hij als jonge speler omging met alle aandacht. Ook komt de rol van pech en mazzel in een voetbalcarrière ter sprake, en het belang van analyseren - zowel als speler als trainer. Een gesprek vol voetbalinzicht, persoonlijke verhalen en de nodige humor.See omnystudio.com/listener for privacy information.

In the rural reaches of Florida's Panhandle, where longleaf pines line quiet roads and neighbors know each other by the sound of their engines, a sexual battery case in the unincorporated community of Fountain exposed how far the state's legal system will go to punish crimes against children. This episode examines the case and the legal architecture behind it.VICTIM PROFILE: The victim was a minor between the ages of twelve and seventeen living in Bay County, Florida. Her identity is protected under state law. What the record shows is that her willingness to come forward and testify at trial formed the foundation of the prosecution's case. Without her testimony, the legal system would have had nothing to act upon. Her courage carried a weight that no verdict can fully acknowledge.THE CRIME: In 2020, allegations surfaced that Brandon Paul Janssen had committed sexual battery against the victim in Fountain, a small unincorporated community in Bay County. The Bay County Sheriff's Office launched an investigation in coordination with the Gulf Coast Children's Advocacy Center, which provided forensic interview support for the minor. During questioning, Janssen confessed to the acts. Prosecutors charged him with two counts of sexual battery on a minor under Florida Statute 794.011(4)(b), each carrying the potential for life imprisonment.THE INVESTIGATION: The Bay County Sheriff's Office led the case with the Gulf Coast Children's Advocacy Center handling victim support and forensic interviews. Janssen's confession became a focal point at trial, with his defense challenging its admissibility on grounds of voluntariness and Miranda compliance. Prosecutor Jeff Moore presented six witnesses before Bay County Circuit Court Judge Timothy Register. The defense also raised hearsay objections to certain testimony. After roughly one hour of deliberation, the jury returned guilty verdicts on both counts.CURRENT STATUS: On November 13, 2023, Janssen received two consecutive life sentences without the possibility of parole. He was designated a sexual predator under Florida law, ensuring lifetime registration and supervision. He appealed to the First District Court of Appeal, which affirmed the convictions and sentences on August 27, 2025, under docket number 1D2023-3176. As of early 2026, Janssen remains incarcerated at Century Correctional Institution.Support Obscura: https://www.patreon.com/obscuracrimepodcast/Our Sponsors:* Check out BetterHelp: https://www.betterhelp.com* Check out Chime: https://chime.com/OBSCURA* Check out Mood and use my code OBSCURA for a great deal: https://mood.com* Check out Quince: https://quince.com/OBSCURA* Check out TruDiagnostic and use my code OBSCURA20 for a great deal: https://www.trudiagnostic.comSupport this podcast at — https://redcircle.com/obscura-a-true-crime-podcast/exclusive-contentAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

In the first episode of 2026, Recycled Content host Kara Pochiro hands hosting duties over to Maite Quinn-Richards, President of Resource Recycling. Maite is joined by APR Board members Michael Westerfield of Dart Container Corporation and Nicole Janssen of Denton Plastics for a preview of the key issues shaping the future of plastics recycling, which will be explored at the 2026 Plastics Recycling Conference (PRC) this February in San Diego. Drawing on perspectives from both brand manufacturing and recycling, the conversation explores current market pressures, recycled content demand, design for recyclability, and the growing role of EPR legislation. The episode also highlights PRC being held alongside the Resource Recycling Conference and the Textile Recovery Summit this year, and why policy, market development, and technical recycling conversations must happen together as the industry heads into 2026.   For more information about PRC visit plasticsrecycling.com.

(Insight Meditation Community of Richmond) There is a group of Theravāda monks right now, walking for peace from Texas to Washington DC. Their journey stands as a quiet yet powerful teaching, reminding us that even in times of unrest and difficulty, peace can begin with how we meet the moment.

(Insight Meditation Community of Richmond) There is a group of Theravāda monks right now, walking for peace from Texas to Washington DC. Their journey stands as a quiet yet powerful teaching, reminding us that even in times of unrest and difficulty, peace can begin with how we meet the moment.

This sermon was pre-recorded due to inclement weather on Sunday, Jan. 25. Stay warm! Support the showContact Village Presbyterian Churchvillagepres.orgcommunications@villagepres.org913-262-4200Have a prayer request? pastoral-care@villagepres.orgFacebook @villagepresInstagram @villagepreschurchYouTube @villagepresbyterianchurchTo join in the mission and ministry of Village Church, go to villagepres.org/giving

Aan tafel deze week: president van De Nederlandsche Bank Olaf Sleijpen, schrijvers Geert Mak en Roxane van Iperen en kunstenaar Julia Janssen.  Presentatie: Joost Vullings Wil je meer weten over de gasten in Buitenhof? Op onze website vind je meer informatie. Daar kan je deze aflevering ook terugkijken en je vindt er natuurlijk nog veel meer gesprekken: https://bit.ly/buitenhof-25jan26 De eerste maanden van zijn termijn als president van De Nederlandsche Bank staan bol van geopolitieke spanningen die ook sterke invloed kunnen hebben op de economie. Aan tafel de nieuwe president van De Nederlandsche Bank Olaf Sleijpen. Hoe moet Europa zich verhouden tot de grillen van Trump? En welk advies heeft hij voor de formerende partijen?  Na een week Davos is het overduidelijk: de wereldorde is veranderd. Hoe moet Europa zich opstellen in een autocratischere wereld waarin ook Amerika steeds verder afdrijft van democratische waarden? En kunnen we de binnenlandse Amerikaanse politiek los zien van het buitenlandbeleid? Daarover schrijvers Geert Mak en Roxane van Iperen. We vertrouwen steeds vaker op ChatGPT en vertellen de AI-chatbot onze diepste geheimen. Dat zal niet zonder gevolgen zijn volgens kunstenaar Julia Janssen. Met haar kunstproject Chadding, dat debuteerde in Davos, laat zij ChatGPT zelf verwoorden hoe het denkt de werkelijkheid te beïnvloeden.

Aan tafel deze week: president van De Nederlandsche Bank Olaf Sleijpen, schrijvers Geert Mak en Roxane van Iperen en kunstenaar Julia Janssen.  Presentatie: Joost Vullings Wil je meer weten over de gasten in Buitenhof? Op onze website vind je meer informatie. Daar kan je deze aflevering ook terugkijken en je vindt er natuurlijk nog veel meer gesprekken: https://bit.ly/buitenhof-25jan26 De eerste maanden van zijn termijn als president van De Nederlandsche Bank staan bol van geopolitieke spanningen die ook sterke invloed kunnen hebben op de economie. Aan tafel de nieuwe president van De Nederlandsche Bank Olaf Sleijpen. Hoe moet Europa zich verhouden tot de grillen van Trump? En welk advies heeft hij voor de formerende partijen?  Na een week Davos is het overduidelijk: de wereldorde is veranderd. Hoe moet Europa zich opstellen in een autocratischere wereld waarin ook Amerika steeds verder afdrijft van democratische waarden? En kunnen we de binnenlandse Amerikaanse politiek los zien van het buitenlandbeleid? Daarover schrijvers Geert Mak en Roxane van Iperen. We vertrouwen steeds vaker op ChatGPT en vertellen de AI-chatbot onze diepste geheimen. Dat zal niet zonder gevolgen zijn volgens kunstenaar Julia Janssen. Met haar kunstproject Chadding, dat debuteerde in Davos, laat zij ChatGPT zelf verwoorden hoe het denkt de werkelijkheid te beïnvloeden.

Kijk uit! In deze aflevering zitten spoilers. Op voorhand ons welgemeende excuus voor iedereen die niet zo gek is op Stranger Things als wij zijn. Tegelijkertijd MOETEN we het erover hebben. Want deze serie heeft ons leven voor een aantal weken in z'n greep gehouden.  We drinken een Vechtdal IPA. Gebrouwen in de Ambachtelijke Vechtdal Brouwerij te Dalfsen. In deze 2-wekelijkse podcast praten Juan en Marc kort bij. De één zorgt voor het bier en de ander voor het onderwerp. 

Negen feiten in amper één maand, waaronder drie moorden. Lange tijd leek Marc Eerdekens zich voor het hof van assisen te moeten verantwoorden voor een reeks gruwelijke moorden, moordpogingen en brandstichtingen in augustus 2020. Maar een hersenbloeding brengt daar mogelijk verandering in: volgens deskundigen is de Houthalense verdachte niet langer toerekeningsvatbaar. ­ Dit is een podcast aflevering van HBVL Crimi met host Tom Verstappen en journalist Geert Houben. ­ CREDITS: Journalist: Geert Houben. Host en redactie: Tom Verstappen. Opname en montage: Siebe Vanheusden en Geert Nies. Muziek: Pieter Santens (House of Media). Chef podcast: Geert Nies.­See omnystudio.com/listener for privacy information.

In the first episode of 2026, Recycled Content host Kara Pochiro hands hosting duties over to Maite Quinn-Richards, President of Resource Recycling. Maite is joined by APR Board members Michael Westerfield of Dart Container Corporation and Nicole Janssen of Denton Plastics for a preview of the key issues shaping the future of plastics recycling, which will be explored at the 2026 Plastics Recycling Conference (PRC) this February in San Diego. Drawing on perspectives from both brand manufacturing and recycling, the conversation explores current market pressures, recycled content demand, design for recyclability, and the growing role of EPR legislation. The episode also highlights PRC being held alongside the Resource Recycling Conference and the Textile Recovery Summit this year, and why policy, market development, and technical recycling conversations must happen together as the industry heads into 2026. For more information about PRC visit plasticsrecycling.com.

Saints du jour 2026-01-15 Saint Arnold Janssen et Saint Rémi by Radio Maria France

15 DE ENERO  - SAN ARNOLDO JANSSEN, PRESBÍTERO Y FUNDADOR

El Señor desafía nuestra fe al realizar algo nuevo precisamente cuando tantas cosas se están derrumbando en la Iglesia.

Het jaar is gestart! Marc en Juan bespreken hun verwachtingen over het nieuwe jaar. Ergens wordt er middenin de aflevering totaal onbedoeld een afslag genomen naar 'het waarom' van het leven. Marc heeft de Zwarte Raaf meegenomen uit de Proeftuin serie van Hertog Jan. Gebrouwen door ons Micha. In deze 2-wekelijkse podcast praten Juan en Marc kort bij. De één zorgt voor het bier en de ander voor het onderwerp. 

On episode 70 of the Innovators Podcast, Avery Smith, a Communications and Marketing Intern at the Iowa State University Research Park, interviews Ella Janssen, Founder of Monologue. In this episode, we dive into how Monologue came to be and the strides Ella has made in her short year in business. Thank you for listening!

In this episode, Rob Jones, Professor and Honorary Consultant in Medical Oncology at the University of Glasgow, UK,  joins us to discuss his journey into oncology, the future of the specialty, and the evolving treatment landscape for genitourinary cancers. From clinical trial design and emerging therapies to European Society for Medical Oncology (ESMO) 2025 takeaways and thoughts on prostate cancer screening, Jones shares practical insights drawn from both research and frontline clinical practice.  Timestamps:     00:00 – Introduction  00:43 – Rob's journey into oncology  04:11 – The next generation of oncologists  08:16 – Clinical trial work  10:20 – Intersection of oncology and nephrology  14:05 – Cardiovascular toxicity  19:25 – European Society for Medical Oncology (ESMO) 2025 bladder cancer takeaways  23:53 – Challenges in designing trials  26:35 – Emerging treatment strategies  30:18 – Prostate cancer screening  34:00 – Magic wishes for healthcare    Disclosure: Jones has received research grants from Astellas, Clovis, Exelixis, Bayer, and Roche; advisory board fees from Janssen, Astellas, Bayer, Novartis, Pfizer, Merck Serono, MSD, Roche, Ipsen, and Bristol Myers Squibb; lecture honoraria from Astellas, Janssen, Bayer, Pfizer, Merck Serono, MSD, Roche, Ipsen, and Bristol Myers Squibb; support for conference attendance from Bayer and Janssen; and participated on a Data Safety Monitoring Board or Advisory Board for Roche.

WGN-TV Meteorologist Mike Janssen joins Wendy Snyder (in for Bob Sirott) to talk about videos of recipes he makes for the Bears games every weekend, including this weekend’s Soul Rolls recipe. He also shares how he started creating his videos, how he got his start in making recipes, and the forecast for this weekend’s Bears […]

Dans cet extrait, l'humoriste raconte comment il a rencontré un suédois, chasseur de rennes... Pendant ces fêtes, retrouvez tous les jours en podcast une archive de l'émission spéciale Noël !Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Dr. Christina Rahm has worked as a medical, clinical, and research scientist in the pharmaceutical, nutraceutical, and biotechnology industries for Janssen, Johnson & Johnson, Biogen Idec/Biogen, UCB, Bristol Meyers Squibb, and Alexion. Additionally, she worked on the corporate side for Pfizer, Biogen, and Janssen and is currently the Chairman of International Science Nutrition Society and Chief Science Officer for ROOT Wellness. Dr. Rahm has also served as a formulator for several companies and manufacturing labs, including her own. She has created multiple provisional patents, proprietary formulas, and trade secrets in addition to authoring her first book, Cure the Causes: Live the Life you Want, Not the One Prescribed. Through years of laboratory research and ethical observations, she has developed a personalized and predictive consulting company working on everything from the environment to DNA and detox wellness plans in which Dr. Rahm helps clients reset their bodies and minds to be spiritually, mentally, emotionally, and physically balanced.

Welcome back to the studio.  This is My Day of Play, where you're taken into the real events and actions of how it happens long before the process of editing or cleaning up.  The original purpose of these episodes was to give my broadcasting students something to edit, to practice with and to call their own.  Then I realized that you are just as important.  Share the reality of how it really went.  We begin things with Victora Castillo creator of Fugitive Hunters Mexico on A&E. Then we'll leap into a revealing conversation with film and screenwriter Joshua Zetumer the creator of Hulu's/FX's Say Nothing. And we'll wrap things up with Sarah Janssen, the editor of one of the biggest selling books of all time… The Almanac!   This is My Day of Play.  Completely unedited in the way of meeting the wizard behind the curtain.  Become a supporter of this podcast: https://www.spreaker.com/podcast/arroe-collins-unplugged-totally-uncut--994165/support.

In jener Zeit wurde der Engel Gabriel von Gott in eine Stadt in Galiläa namens Nazaret zu einer Jungfrau gesandt. Sie war mit einem Mann namens Josef verlobt, der aus dem Haus David stammte. Der Name der Jungfrau war Maria.Der Engel trat bei ihr ein und sagte: Sei gegrüßt, du Begnadete, der Herr ist mit dir. Sie erschrak über die Anrede und überlegte, was dieser Gruß zu bedeuten habe.Da sagte der Engel zu ihr: Fürchte dich nicht, Maria; denn du hast bei Gott Gnade gefunden. Siehe, du wirst schwanger werden und einen Sohn wirst du gebären; dem sollst du den Namen Jesus geben. Er wird groß sein und Sohn des Höchsten genannt werden. Gott, der Herr, wird ihm den Thron seines Vaters David geben. Er wird über das Haus Jakob in Ewigkeit herrschen und seine Herrschaft wird kein Ende haben.Maria sagte zu dem Engel: Wie soll das geschehen, da ich keinen Mann erkenne?Der Engel antwortete ihr: Heiliger Geist wird über dich kommen und Kraft des Höchsten wird dich überschatten. Deshalb wird auch das Kind heilig und Sohn Gottes genannt werden. Siehe, auch Elisabet, deine Verwandte, hat noch in ihrem Alter einen Sohn empfangen; obwohl sie als unfruchtbar gilt, ist sie schon im sechsten Monat. Denn für Gott ist nichts unmöglich.Da sagte Maria: Siehe, ich bin die Magd des Herrn; mir geschehe, wie du es gesagt hast.Danach verließ sie der Engel.(© Ständige Kommission für die Herausgabe der gemeinsamen liturgischen Bücher im deutschen Sprachgebiet)Das Lukasevangelium ist der erste Teil eines Doppelwerks; der zweite Teil ist die Apostelgeschichte. Lukas will den engen Zusammenhang zwischen der Verkündigung Jesu und dem österlichen Aufbruch der Kirche zeigen. Er richtet sein Werk an Theophilos (deutsch: Freund Gottes), den er tiefer in den Glauben einführen will. Als Verfasser gilt traditionell Lukas, der Begleiter des Paulus. Er schreibt einen eleganten Stil, der den kulturellen Anspruch des Christentums widerspiegelt.

Mit der Geburt Jesu Christi war es so: Maria, seine Mutter, war mit Josef verlobt; noch bevor sie zusammengekommen waren, zeigte sich, dass sie ein Kind erwartete – durch das Wirken des Heiligen Geistes. Josef, ihr Mann, der gerecht war und sie nicht bloßstellen wollte, beschloss, sich in aller Stille von ihr zu trennen. Während er noch darüber nachdachte, siehe, da erschien ihm ein Engel des Herrn im Traum und sagte: Josef, Sohn Davids, fürchte dich nicht, Maria als deine Frau zu dir zu nehmen; denn das Kind, das sie erwartet, ist vom Heiligen Geist. Sie wird einen Sohn gebären; ihm sollst du den Namen Jesus geben; denn er wird sein Volk von seinen Sünden erlösen. Dies alles ist geschehen, damit sich erfüllte, was der Herr durch den Propheten gesagt hat: Siehe: die Jungfrau wird ein empfangen und einen Sohn gebären, und sie werden ihm den Namen Immanuel geben, das heißt übersetzt: Gott mit uns. Als Josef erwachte, tat er, was der Engel des Herrn ihm befohlen hatte, und nahm seine Frau zu sich. (Mt 1,18-24)(© Ständige Kommission für die Herausgabe der gemeinsamen liturgischen Bücher im deutschen Sprachgebiet)

Zur Zeit des Herodes, des Königs von Judäa, gab es einen Priester namens Zacharías, der zur Abteilung des Abíja gehörte. Seine Frau stammte aus dem Geschlecht Aarons; ihr Name war Elisabet. Beide lebten gerecht vor Gott und wandelten untadelig nach allen Geboten und Vorschriften des Herrn. Sie hatten keine Kinder, denn Elisabet war unfruchtbar und beide waren schon in vorgerücktem Alter. Es geschah aber: Als seine Abteilung wieder an der Reihe war und er den priesterlichen Dienst vor Gott verrichtete, da traf ihn, wie nach der Priesterordnung üblich, das Los, in den Tempel des Herrn hineinzugehen und das Rauchopfer darzubringen. Während er nun zur festgelegten Zeit das Rauchopfer darbrachte, stand das ganze Volk draußen und betete. Da erschien dem Zacharías ein Engel des Herrn; er stand auf der rechten Seite des Rauchopferaltars. Als Zacharías ihn sah, erschrak er und es befiel ihn Furcht. Der Engel aber sagte zu ihm: Fürchte dich nicht, Zacharías! Dein Gebet ist erhört worden. Deine Frau Elisabet wird dir einen Sohn gebären; dem sollst du den Namen Johannes geben. Du wirst dich freuen und jubeln und viele werden sich über seine Geburt freuen. Denn er wird groß sein vor dem Herrn. Wein und berauschende Getränke wird er nicht trinken und schon vom Mutterleib an wird er vom Heiligen Geist erfüllt sein. Viele Kinder Israels wird er zum Herrn, ihrem Gott, hinwenden. Er wird ihm mit dem Geist und mit der Kraft des Elíja vorangehen, um die Herzen der Väter den Kindern zuzuwenden und die Ungehorsamen zu gerechter Gesinnung zu führen und so das Volk für den Herrn bereit zu machen. Zacharías sagte zu dem Engel: Woran soll ich das erkennen? Denn ich bin ein alter Mann und auch meine Frau ist in vorgerücktem Alter. Der Engel erwiderte ihm: Ich bin Gábriel, der vor Gott steht, und ich bin gesandt worden, um mit dir zu reden und dir diese frohe Botschaft zu bringen. Und siehe, du sollst stumm sein und nicht mehr reden können bis zu dem Tag, an dem dies geschieht, weil du meinen Worten nicht geglaubt hast, die in Erfüllung gehen, wenn die Zeit dafür da ist. Inzwischen wartete das Volk auf Zacharías und wunderte sich, dass er so lange im Tempel blieb. Als er dann herauskam, konnte er nicht mit ihnen sprechen. Da merkten sie, dass er im Tempel eine Erscheinung gehabt hatte. Er gab ihnen nur Zeichen und blieb stumm. Als die Tage seines Dienstes zu Ende waren, kehrte er nach Hause zurück. Bald darauf wurde seine Frau Elisabet schwanger und lebte fünf Monate lang zurückgezogen. Sie sagte: Der Herr hat mir geholfen; er hat in diesen Tagen gnädig auf mich geschaut und mich von der Schmach befreit, mit der ich unter den Menschen beladen war.(© Ständige Kommission für die Herausgabe der gemeinsamen liturgischen Bücher im deutschen Sprachgebiet)

In jener Zeit, als Jesus in den Tempel ging und dort lehrte, kamen die Hohepriester und die Ältesten des Volkes zu ihm und fragten: In welcher Vollmacht tust du das und wer hat dir diese Vollmacht gegeben? Jesus antwortete und sprach zu ihnen: Auch ich will euch eine Frage stellen. Wenn ihr mir darauf antwortet, dann werde ich euch sagen, in welcher Vollmacht ich das tue. Woher stammte die Taufe des Johannes? Vom Himmel oder von den Menschen? Da überlegten sie und sagten zueinander: Wenn wir antworten: Vom Himmel!, so wird er zu uns sagen: Warum habt ihr ihm dann nicht geglaubt? Wenn wir aber antworten: Von den Menschen!, dann müssen wir uns vor den Leuten fürchten; denn alle halten Johannes für einen Propheten. Darum antworteten sie Jesus: Wir wissen es nicht. Da erwiderte er: Dann sage auch ich euch nicht, in welcher Vollmacht ich das tue. (© Ständige Kommission für die Herausgabe der gemeinsamen liturgischen Bücher im deutschen Sprachgebiet)

Buch des Ursprungs Jesu Christi, des Sohnes Davids, des Sohnes Abrahams: Abraham zeugte den Ísaak, Ísaak zeugte den Jakob, Jakob zeugte den Juda und seine Brüder. Juda zeugte den Perez und den Serach mit der Tamar.Perez zeugte den Hezron, Hezron zeugte den Aram, Aram zeugte den Amminádab, Amminádab zeugte den Nachschon, Nachschon zeugte den Salmon. Salmon zeugte den Boas mit der Rahab. Boas zeugte den Obed mit der Rut. Obed zeugte den Ísai, Ísai zeugte David, den König. David zeugte den Salomo mit der Frau des Urija. Salomo zeugte den Rehabeam, Rehabeam zeugte den Abija, Abija zeugte den Asa, Asa zeugte den Joschafat, Joschafat zeugte den Joram, Joram zeugte den Usija. Usija zeugte den Jotam, Jotam zeugte den Ahas, Ahas zeugte den Hiskija, Hiskija zeugte den Manasse, Manasse zeugte den Amos, Amos zeugte den Joschija. Joschija zeugte den Jojachin und seine Brüder; das war zur Zeit der Babylonischen Gefangenschaft.Nach der Babylonischen Gefangenschaft zeugte Jojachin den Schealtiël, Schealtiël zeugte den Serubbabel, Serubbabel zeugte den Abihud, Abihud zeugte den Eljakim, Eljakim zeugte den Azor. Azor zeugte den Zadok, Zadok zeugte den Achim, Achim zeugte den Eliud, Eliud zeugte den Eleasar, Eleasar zeugte den Mattan, Mattan zeugte den Jakob.Jakob zeugte den Josef, den Mann Marias; von ihr wurde Jesus geboren, der der Christus genannt wird.Im Ganzen sind es also von Abraham bis David vierzehn Generationen, von David bis zur Babylonischen Gefangenschaft vierzehn Generationen und von der Babylonischen Gefangenschaft bis zu Christus vierzehn Generationen.(© Ständige Kommission für die Herausgabe der gemeinsamen liturgischen Bücher im deutschen Sprachgebiet)

In jener Zeit sprach Jesus zu den Hohepriestern und den Ältesten des Volkes: Was meint ihr? Ein Mann hatte zwei Söhne. Er ging zum ersten und sagte: mein Kind, geh und arbeite heute im Weinberg! Er antwortete: Ich will nicht. Später aber reute es ihn und er ging hinaus. Da wandte er sich an den zweiten und sagte zu ihm dasselbe. Dieser antwortete: Ja, Herr – und ging nicht hin. Wer von den beiden hat den Willen seines Vaters erfüllt? Sie antworteten: Der erste. Da sagte Jesus zu ihnen: Amen, ich sage euch: Die Zöllner und die Dirnen gelangen eher in das Reich Gottes als ihr. Denn Johannes ist zu euch gekommen auf dem Weg der Gerechtigkeit und ihr habt ihm nicht geglaubt; aber die Zöllner und die Dirnen haben ihm geglaubt. Ihr habt es gesehen und doch habt ihr nicht bereut und ihm nicht geglaubt. (© Ständige Kommission für die Herausgabe der gemeinsamen liturgischen Bücher im deutschen Sprachgebiet)

In jener Zeit, als Jesus in den Tempel ging und dort lehrte, kamen die Hohepriester und die Ältesten des Volkes zu ihm und fragten: In welcher Vollmacht tust du das und wer hat dir diese Vollmacht gegeben? Jesus antwortete und sprach zu ihnen: Auch ich will euch eine Frage stellen. Wenn ihr mir darauf antwortet, dann werde ich euch sagen, in welcher Vollmacht ich das tue. Woher stammte die Taufe des Johannes? Vom Himmel oder von den Menschen? Da überlegten sie und sagten zueinander: Wenn wir antworten: Vom Himmel!, so wird er zu uns sagen: Warum habt ihr ihm dann nicht geglaubt? Wenn wir aber antworten: Von den Menschen!, dann müssen wir uns vor den Leuten fürchten; denn alle halten Johannes für einen Propheten. Darum antworteten sie Jesus: Wir wissen es nicht. Da erwiderte er: Dann sage auch ich euch nicht, in welcher Vollmacht ich das tue. (© Ständige Kommission für die Herausgabe der gemeinsamen liturgischen Bücher im deutschen Sprachgebiet)

JCO Editor-in-Chief Dr. Jonathan Friedberg is joined by colleagues Dr. Jennifer Woyach, Dr. Wojciech Jurczak, and Dr. Matthew Davids to discuss simultaneous publications presented at ASH 2025 on pertibrutinib, a new upfront treatment option for patients with chronic lymphocytic leukemia. TRANSCRIPT The disclosures for guests on this podcast can be found in the show notes. Dr. Jonathan Friedberg: I'm Jonathan Friedberg, editor of Journal of Clinical Oncology, and welcome to JCO After Hours, where we are covering two manuscripts that were presented at the American Society of Hematology meeting 2025 in Orlando, Florida. I am delighted to be joined by colleagues on this call to discuss these pivotal manuscripts which cover the topic of pirtobrutinib, a new upfront treatment option for patients with chronic lymphocytic leukemia. I will first just introduce our guests, Dr. Woyach. Dr. Jennifer Woyach: Hi, my name is Jennifer Woyach. I am from the Ohio State University. Dr. Wojciech Jurczak: Hello, I am Wojciech Jurczak, working at the National Research Institute of Oncology in Krakow, Poland. Dr. Matthew Davids: Hi, I am Matthew Davids from Dana-Farber Cancer Institute in Boston. Dr. Jonathan Friedberg: We are going to start by just learning a little bit about these two trials that were both large, randomized phase 3 studies that I think answered some definitive questions. We will start with your study, Jennifer. If you could just describe the design of your study and the patient population. Dr. Jennifer Woyach: Absolutely. So this is the BRUIN CLL-314 study, and this is a phase 3 randomized trial of pirtobrutinib versus ibrutinib in patients with CLL or SLL who had not previously been treated with a covalent BTK inhibitor. The patients were both treatment-naive and relapsed/refractory, about one-third of the patients treatment-naive, the rest relapsed/refractory, and they were stratified based upon 17p deletion and the number of prior lines of therapy. The primary objective was looking at non-inferiority of overall response rate over the entire treated population as well as the relapsed/refractory patient population. Key secondary objectives included progression-free survival in the intention-to-treat and the smaller relapsed/refractory and treatment-naive populations. Dr. Jonathan Friedberg: And just comment a little bit on the risk of the patients. Dr. Jennifer Woyach: This study was fairly typical of this cohort of patients. Within the relapsed/refractory patient population, there was a median of one prior line of therapy in each of the groups, up to nine prior lines of therapy in the patients included on the study. For the overall cohort, about two-thirds of the patients were IGHV unmutated, about 15% had 17p deletion, 30% had TP53 mutations, and about 35% to 40% had a complex karyotype, which is three or more abnormalities. Dr. Jonathan Friedberg: And what were your findings? Dr. Jennifer Woyach: Regarding the primary outcome, which is the focus of the publication, we did find that pirtobrutinib was indeed non-inferior and actually superior to ibrutinib for overall response rate throughout the entire patient population and in both the relapsed/refractory and treatment-naive cohorts. PFS is a little bit immature at this time but is trending towards also being significantly better in pirtobrutinib-treated patients compared with ibrutinib-treated patients. Probably most significantly, we found this to be the case in the treatment-naive cohort where there was a striking trend to an advantage of pirtobrutinib versus ibrutinib. Dr. Jonathan Friedberg: And the follow-up that you have on that progression-free survival? Dr. Jennifer Woyach: So we have about 18 months follow-up on progression-free survival. Dr. Jonathan Friedberg: The second study, Wojciech, can you just go through the design and patient population that you treated? Dr. Wojciech Jurczak: Thank you, Dr. Friedberg, for this question. So the BRUIN CLL-313 study was, in fact, the first phase 3 study with pirtobrutinib in exclusively untreated CLL patients. It was a randomized study where we challenged pirtobrutinib versus bendamustine-rituximab. At the time we designed the protocol, bendamustine-rituximab was an option as a standard of care, and Bruton tyrosine kinase monotherapy was used far more commonly than nowadays. The primary target of the study was progression-free survival. We took all untreated patients except for those with 17p deletions. Therefore, it is a good representation for intermediate risk. We had about 60% of the population, 56 to be precise, which was unmutated, evenly distributed into two treatment arms. 17p deleted cases were excluded, but we had about 7% and 8% of TP53 mutated patients as well as about 11% and 7%, respectively, in the pirtobrutinib and bendamustine-rituximab arm of patients with complex karyotype. The progression-free survival was in favor of pirtobrutinib and was assessed by an independent review committee. What is important is that the progression-free survival of the bendamustine-rituximab arm was actually similar to the other studies addressing the same questions, like the comparison with ibrutinib in the ALLIANCE study or zanubrutinib in the SEQUOIA study. What was different was the hazard ratio. In our study, it was 0.20. It was one of the longest effect sizes noted in the frontline BTK study. It represented an 80% reduction in progression-free survival or death. If we compare it to ibrutinib or zanubrutinib, it was 0.39 and 0.42 respectively. Presumably, this great effect contributed towards a trend of overall survival difference. Although survival data are not mature enough, there is a clear trend represented by three patients we lost in the pirtobrutinib arm versus 10 patients lost in the bendamustine-rituximab arm. This trend in overall survival is becoming statistically significant despite the fact that there was a possibility of crossover, and effectively 52.9 patients, which means 18 out of 34 patients relapsing in the bendamustine-rituximab arm, were treated by pirtobrutinib. Dr. Jonathan Friedberg: I am going to turn it over to Matt. The question is: why study pirtobrutinib in this patient population? And then with these two studies, how do you find the patients that were treated, are they representative of people who you see? And do you see this maybe being approved and more widely available? Dr. Matthew Davids: I think in terms of the first question, why study this in a frontline population, we have seen very impressive data with pirtobrutinib in a very difficult-to-treat population of CLL patients. This was from the original BRUIN phase 1/2 study where most of the patients had at least two or three lines of therapy, often both a covalent BTK inhibitor and the BCL2 inhibitor venetoclax, and yet they were still responding to pirtobrutinib. The drug was also very well tolerated in that early phase experience. And actually, we have seen phase 3 data from the BRUIN 321 study comparing pirtobrutinib to bendamustine and rituximab in a relapse population as well. So I think that really motivated these studies to look at pirtobrutinib as a first therapy. You know, often in other cancers of course, we want to use our best therapy first, and I think these studies are an initial step at looking at that. In terms of the second question around the patient population, these are pretty representative patient populations, I would say, for most frontline CLL studies. We see patients who are a bit younger and fitter than sort of the general population of CLL patients who are treated in clinical practice, and I think that is true here as well. Median age in the sort of mid-60s here is a bit younger than the typical patients we are treating in practice. But that is not different from other CLL frontline studies that we have seen recently, so I think it makes it a little bit easier as we kind of think across studies to feel comfortable that these are relatively similar populations. Dr. Jonathan Friedberg: How do you see this either getting regulatory approval or potentially being used compared to current standard of care options? Dr. Matthew Davids: So my understanding is that both of these trials were designed with registrational intent in the frontline setting, and they are both positive studies. That is certainly very encouraging in terms of the potential for an approval here. We have seen in terms of the FDA recently some concerns around the proportion of patients who are coming from North America, and my understanding is that is relatively low on these two studies. But nonetheless, the datasets are very impressive, and so I think it is certainly supportive of regulatory approval for frontline pirtobrutinib. Dr. Jonathan Friedberg: I will ask Jennifer a question. The control arm in your study was ibrutinib, and I think many in the audience may recognize that newer, second-generation BTK inhibitors like acalabrutinib and zanubrutinib are more frequently used now if monotherapy is decided. How do you respond to that, and how would you put your results in your pirtobrutinib arm in context with what has been observed with those agents? Dr. Jennifer Woyach: Yeah, that is a great question. Even though in the United States we are predominantly using acalabrutinib or zanubrutinib when choosing a monotherapy BTK inhibitor, this is actually not the case throughout the entire world where ibrutinib is still used very frequently. The head-to-head studies of both acalabrutinib and zanubrutinib compared to ibrutinib have shown us pretty well what the safety profile and efficacy profile of the second-generation BTK inhibitors is. So even though we do not have a head-to-head study of acalabrutinib or zanubrutinib versus pirtobrutinib, I think, given the entirety of data that we have with all of the covalent BTK inhibitors, I think we can safely look at the pirtobrutinib arm here, how the ibrutinib arm compares or performs in context with those other clinical trials. And though we really can not say anything about pirtobrutinib versus acalabrutinib or zanubrutinib, I think we can still get a good idea of what might be the clinical scenarios in which you might want to choose pirtobrutinib. Dr. Jonathan Friedberg: And Wojciech, do you agree with that? Obviously, I think you have acknowledged that chemoimmunotherapy is rarely used anymore as part of upfront treatment for CLL. So, I guess a similar question. If you were to put the pirtobrutinib result in your study in context with, I guess, more contemporary type controls, would you agree that it is competitive? Dr. Wojciech Jurczak: Well, I think that that was the last study ever where bendamustine-rituximab was used as a comparator arm. So we should notice that smashing difference. Because if we look at the progression-free survival at two years, we have 93.4% in pirtobrutinib arm versus 70.7% in bendamustine-rituximab arm. Bendamustine-rituximab arm did the same as in the other trials, like ALLIANCE or SEQUOIA. Pirtobrutinib did exceptionally well, as pirto is not just the very best BTK inhibitor overcoming the resistance, but perhaps even more important for the first line, it is very well tolerated and is a very selective drug. Now, if we look at treatment-related adverse events, the discontinuation rate, they were hardly ever seen. If we compared the adverse events in exposure-adjusted incidence, literally all adverse events were two or three times higher in bendamustine-rituximab arm except for the bleeding tendency, which however was predominantly in CTCAE grade 1 and 2 with just 0.7% of grade 3 hemorrhage. Therefore, I think that we should actually put the best and the safest drugs upfront if we may, and pirtobrutinib is, or should be, the first choice if we choose monotherapy. Now, I understand that we are not presenting you the data of pirtobrutinib in combination with anti-CD20 or with BCL2 inhibitors, but that is to come. Dr. Jonathan Friedberg: Matt, how would you envision, were regulatory approval granted and this were an option, using this in the upfront patient population? Is there anybody who you would preferentially use this or start on this treatment? Or would this be something that you would tend to reserve for second line? Dr. Matthew Davids: So I would say that in general for most of my patients who would want to start with a continuous BTK inhibitor, I would still use a covalent BTK inhibitor, and I say that for a couple of reasons despite the very promising data from these studies. The first is that the follow-up for both of these phase 3 trials is still quite short, in the range of a median 18 to 24 months. And we know that CLL is a marathon, not a sprint, and these patients are going to probably be living for a very long time. And we do have much longer follow-up from the covalent BTK inhibitors, median of 10-year follow-up with ibrutinib and five to six years with zanubrutinib and acalabrutinib respectively. And you know, I do not think that the pirtobrutinib is going to fall off a cliff after two years, but on the other hand, I think there is a lot of value to long-term data in this disease, and that is why I think for most of my patients I would stick with covalent BTK inhibitors. But the other important factor that we need to consider is patients who are younger and may have many different CLL treatments over the years. We have to be very careful, I think, about how we sequence these drugs. We know right now that we can start with covalent BTK inhibitors and then subsequently patients will respond well to the non-covalent inhibitor pirtobrutinib in later lines of therapy. But right now we do not have prospective data the other way around. So how will the patients on these studies who progress on pirtobrutinib respond to covalent BTK inhibitors? We do not know yet. There have not been a lot of progression events, which is great, but we would like to see some data in that respect to feel more comfortable with that sequence. Now, I do think that particularly for older patients and those who have significant cardiovascular comorbidities, if they wanted to go on a continuous BTK inhibitor, I do think these data really strongly support using pirtobrutinib as the BTK inhibitor of choice in that population. In particular, the cardiovascular risks with pirtobrutinib seem to be quite low. I was very struck in the comparison with BR that the rate of AFib was equivalent between the two arms of the study. And that is really the first time we have seen that with any of these BTK inhibitors, no elevated risk of AFib in a randomized study. I think that is the population where it will get the most traction first, is the upfront, sort of older patient with significant cardiovascular comorbidities. And as the data from these studies mature, I think that we will start to see more widespread use of pirtobrutinib in the frontline setting. Dr. Jonathan Friedberg: Jennifer, I am just curious if you have any personal experience or heard anecdotally about after progression on pirtobrutinib the use of other BTK inhibitors and whether there is a growing experience there. Dr. Jennifer Woyach: I do not think that there is much clinical experience, you know, as Matt alluded to, it certainly has not been tested yet. There has been some data in relapsed CLL suggesting that in people who have resistance mutations to covalent BTK inhibitors after treatment with pirtobrutinib, sometimes those mutations go away. I think most of us are concerned that they are probably not actually gone but maybe in compartments that we just have not sampled, suggesting that sort of approach where you might sequence a covalent inhibitor after a non-covalent in somebody who had already been resistant probably would not work that well. But, you know, in this setting where people had never been exposed to a covalent BTK inhibitor before, we really have no idea what the resistance patterns are going to be like. We assume they will be the same as what we have seen in relapsed CLL, but I think we just need some longer follow-up to know for sure. Dr. Wojciech Jurczak: If I may confront Dr. Davids about the use of covalent BTK inhibitors upfront, well, I think that we should abandon the idea of using the first and the second and the third generation, at least if we don't have medical lines. If we endlessly block the same pathway, it is not going to be effective. So if pirtobrutinib gets approval in first, second line, we do not necessarily have to use it in the first line. I am not here in a position to defend that we should treat patients with pirtobrutinib upfront and not BCL2 time-limited regimen. However, the way I look at CLL patients when choosing therapy is not just how should I treat them now, but what would be the best regimen in 5, 10 years if I have to re-treat them. And in some instances, the idea may be that in this setting we would like to have a BTK inhibitor upfront to have a BCL2 inhibitor later to make it time-limited. Although I understand and I agree with Matthew that if we have an elderly, fragile population, then the charm of having a drug taken once a day in a tablet with literally few cardiovascular adverse events might be an option. Dr. Jonathan Friedberg: And I will give Matt the last word whether he wants to respond to that, and also just as a forward-looking issue, I know both investigators have implied that there will be future studies looking at combinations with pirtobrutinib, and if you have any sense as to what you would be looking for there. Dr. Matthew Davids: The field really is heading toward time-limited therapy for most patients, I would say. There is a bit of a discrepancy right now in the field between sort of what we are doing in academic practice and what is done sort of more widely in community practice. And so right now we are going to see evolving datasets comparing these approaches. We are already seeing data now from the CLL17 study with ibrutinib comparing continuous to time-limited venetoclax-based therapy, and we are seeing similar efficacy benefits from these time-limited therapies without the need for continuous treatment. And so that is where I think some of the future studies with pirtobrutinib combining it with venetoclax and other partners are so important. Fortunately, several of these studies are already ongoing, including a phase 3 trial called CLL18, which is looking at pirtobrutinib with venetoclax, comparing that to venetoclax and obinutuzumab. So I am optimistic that we are going to be developing these very robust datasets where we can actually use pirtobrutinib in the frontline setting as a time-limited therapy as a component of a multi-drug regimen. So far, those early data are very promising. Dr. Wojciech Jurczak: Perhaps last but not least, in a single center we have treated over 300 patients with pirtobrutinib. So eventually some of them relapsed. And I must say that our experience on BCL2 inhibitors, not just venetoclax but including sonrotoclax, are appealingly good. Therefore, by using pirtobrutinib even earlier, we do not block the efficacy of other compounds. Dr. Jonathan Friedberg: All right. Well, I want to thank all of our speakers. I also want to congratulate our two guests who presented these very influential papers at the ASH Annual Meeting, and chose to publish them in JCO, so we thank you for that, and Dr. Davids for your commentary - really appreciated. That is this episode of JCO After Hours. Thank you for your attention. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Disclosures Dr. Wojciech Jurczak Consulting or Advisory Role: BeiGene, Lilly, Abbvie/Genentech, Takeda, Roche, AstraZeneca Research Funding: Roche, Takeda, Janssen-Cilag, BeiGene, AstraZeneca, Lilly, Abbvie/Genentech Dr. Jennifer Woyach Consulting or Advisory Role: Pharmacyclics, Janssen, AstraZeneca, Beigene, Loxo, Newave Pharmaceutical, Genentech, Abbvie, Merck Research Funding: Company name: Janssen, Schrodinger, beone, Abbvie, Merck, Loxo/Lilly Dr. Matthew Davids Honoraria: Curio Science, Aptitude Health, Bio Ascend, PlatformQ Health, Plexus Consulting or Advisory Role: Genentech, Janssen, Abbvie, AstraZeneca, Adaptive Biotechnologies, Ascentage Pharma, BeiGene, Lilly, Bristol-Myers Squibb, Genmab, Merck, MEI Pharma, Nuvalent, Inc., Galapagos NV, Schroedinger Research Funding: Ascentage Pharma, Novartis, MEI Pharma, AstraZeneca  

Redemption is not just a future hope—it's a present reality in Christ.

Cam Janssen, born in St. Louis and raised in Eureka, Missouri is the first ever born-and-raised St. Louisan to suit up in the NHL. He was famous for the rough stuff in hockey, and takes great pride in it. He spent several seasons exciting the crowds at the Enterprise Center. Cam has a great way of telling a story…Enjoy!

At the age of 14, Michaela Janssen Pohl became a caregiver for her mother, who lives with MS. I think most of us can agree that just being a teenager carries with it more than enough challenges. Those adolescent years are the years when just about everything in life starts changing. Imagine adding the responsibilities of being a caregiver to all the other things going on in a 14-year-old girl's life. Michaela joins me this week to explain how she found ways to survive and thrive in what can only be described as a challenging situation for any teenager. We'll also explain why you might want to think a little differently about Giving Tuesday this year. We're sharing all the details about the Phase 2 clinical trial focusing on Moderna's investigational Epstein-Barr vaccine and MS (and we'll explain why that might turn out to be important!) We're talking about how MS impacts women's health issues with this year's winner of the Rachel Horne Prize for Women's Research in Multiple Sclerosis, Dr. Kristen Krysko. And we're sharing the results of the Phase 2 clinical trial for PIPE-307, an investigational remyelination therapy. We have a lot to talk about! Are you ready for RealTalk MS??! It's Giving Tuesday (and why that matters more this year than ever before)  :22 This Week: Becoming a caregiver for a parent with MS when you're 14 years old  3:27 A clinical trial focused on an EBV vaccine and MS is recruiting participants  4:25 Dr. Kristen Krysko discusses MS and women's health issues  7:52 Results from the Phase 2 clinical trial for PIPE-307 remyelination therapy  13:48 Michaela Janssen Pohl shares her story of becoming a caregiver at the age of 14  16:55 Share this episode  33:20 Next week's episode  33:40 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/431 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com DONATE: The National MS Society https://nationalmssociety.org/donate SIGN UP: Become an MS Activist https://nationalmssociety.org/advocacy PARTICIPATE: Phase 2 Clinical Trial for Moderna's EBV Vaccine and MS https://clinicaltrials.gov/study/NCT06735248 Email: WeCareClinicalTrials@modernatx.com JOIN: The RealTalk MS Facebook Group https://facebook.com/groups/realtalkms REVIEW: Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 431 Guests: Dr. Kristen Krysko, Michaela Janssen Pohl Privacy Policy

God's Word helps us truly believe in Him that we may find true life in Him.

Rechte Straftaten von jungen Menschen haben in den letzten Jahren deutlich zugenommen. Ein Grund sind die vielen Krisen, mit denen Jugendliche konfrontiert sind, sagt Ausstiegsberaterin Lena Janssen. Die Entwicklung im Westen wird dabei unterschätzt. Janssen, Lena www.deutschlandfunkkultur.de, Interview

Ben Ennis and Brent Gunning wrap up the morning by speaking with Sportsnet.ca's Luke Fox about the Toronto Maple Leafs. They discuss expectations for Brad Treliving's media availability, the impact of David Kämpf, and the toll of injuries on the team. They also speculate on the return of Auston Matthews and whether the Leafs might have missed their championship window. After the break, former NHL player Cam Janssen (25:50) shares his insights on the Leafs and St. Louis Blues, including concerns about Mitch Marner's absence and Craig Berube's coaching status. Ben and Brent conclude with the Crown Royal Canadian moment.The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the position of Rogers Sports & Media or any affiliate.

Elias Janssen is one of the stars of the new Netflix film IN YOUR DREAMS which is out today! The animated film is fun for the whole family and Gavin got to sit down with him to talk about the process and what it was like, as well as his personal life and career.

No other book has had such a vast and formative effect on the history of the world as the Holy Bible.

Do you know that you are also God's provision to others?

Today we celebrate and remember the saints that have gone before us.Sunday service times are 9 a.m., 11 a.m., and 4 p.m. at the Mission Campus in Prairie Village, Kansas, and 10 a.m. at the Antioch Campus in Overland Park, Kansas. If you are unable to attend in person, you can worship online at villagepres.org/online. Support the showContact Village Presbyterian Churchvillagepres.orgcommunications@villagepres.org913-262-4200Have a prayer request? pastoral-care@villagepres.orgFacebook @villagepresInstagram @villagepreschurchYouTube @villagepresbyterianchurchTo join in the mission and ministry of Village Church, go to villagepres.org/giving

(Insight Meditation Society - Retreat Center) The Third Noble Truth is about the cessation of dukkha (unsatisfactoriness) and the realization of Nibbāna (awakening). Through inspiring stories of modern-day figures like Mae Chee Kaew and Dipa Ma, we see that awakening is possible in this very life.

(Insight Meditation Society - Retreat Center) After a brief overview of the four Bbrahmavihāras and their interconnections, the session continues with a brief reflection on upekkhā (equanimity), followed by a guided equanimity meditation.

Jacqueline (https://jacquelinejanssen.com/) has turned all she has learned about mental illness from her son's mental health journey into incredible advocacy. Her latest book, Every Homeless Person Has a Mother, chronicles Jacqueline's experience as a parent of an adult child with schizoaffective disorder. Jacqueline's son's battle with mental illness started when he was 19 years old. Jacqueline talks about the myriad of therapies and treatments her son received and how he ultimately ended up homeless as a result of anosognosia (https://www.nami.org/about-mental-illness/common-with-mental-illness/anosognosia/) or the lack of ability to recognize and treat his mental illness. Jacqueline has been a tireless advocate for families through her own work and with NAMI (https://www.nami.org/) and encourages families to get involved in their local NAMI chapters. Jacqueline emphasizes that when a loved one is incapable of making decisions for his or her own good, HIPAA (https://www.cdc.gov/phlp/php/resources/health-insurance-portability-and-accountability-act-of-1996-hipaa.html) allows mental health providers to talk to families. Jacqueline also discusses strategies for reunification of families if there is estrangement due to mental illness. Jacqueline graciously shares many resources with listeners:Family Rights and HIPAA Facts: https://drive.google.com/file/d/1W6DO-beIMgMww0xH1QTUBECiSXd85W8H/view?usp=drive_link; HIPAA Decision Tree: https://drive.google.com/file/d/1DsI-DpSCFrZLfgCknTqjaMqXTavh0AGu/view?usp=drive_link; Family Involvement Accelerates Recovery: https://drive.google.com/file/d/1IoCvWj7H56K-F4qtSL5hiGHriEn6Nk8U/view?usp=drive_link; Every Homeless Person Has A Mother: https://everyhomelesspersonhasamother.substack.com; https://www.nationalshatteringsilencecoalition.org/; What I Wish I'd Known: https://drive.google.com/file/d/1KnkPLJKF7TCNyvTwxgnZIhtAcDOCgoYQ/view?usp=drive_link

(Insight Meditation Society - Retreat Center) Right Effort, the 6th step on the Noble Eightfold Path, is not about striving or straining, it is about learning to guide the mind with wisdom and care. In this talk, we reflect on the Four Great Efforts: 1) Preventing the arising of unwholesome states, 2) Abandoning those that have already arisen, 3) Cultivating wholesome qualities, 4) Extending and nourishing wholesome states that are present. These four ways of applying effort, remembered with the acronym PACE, offer a clear and practical way to work with unwholesomeness and support wholesomeness.

(Insight Meditation Society - Retreat Center)

(Insight Meditation Society - Retreat Center) While walking meditation often receives less attention than sitting meditation, it offers numerous benefits worth exploring. In this talk, we will go into the 'Walking Meditation' sutta, where the Buddha outlines five benefits of this practice. We'll conclude with a bonus benefit.